Large gap with delayed quotes
|
Last quote
04/27/2026
-
19:14:42
|
Bid
04/27/2026 -
19:14:58
|
Bid Volume |
Ask
04/27/2026 -
19:14:58
|
Ask Volume |
|---|---|---|---|---|
|
88.34
+3.43
(
+4.04% )
|
88.24
|
100 |
88.44
|
100 |
Analysis date: 24.04.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 31.03.2026.
Interest
Weak
Weak
Two stars since 10.04.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 10.04.2026 at a price of 85.05.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded above its moving average since 31.03.2026.
4wk Rel Perf
4.81%
4.81%
The four-week dividend-adjusted overperformance versus SP500 is 4.81%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 31.03.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.63%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.36%.
Mkt Cap in $bn
6.93
6.93
With a market capitalization between $2 & $8bn, KYMERA THERAPEUTICS is considered a mid-cap stock.
G/PE Ratio
-0.68
-0.68
A negative ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) indicates that either the forecasted growth is decelerating (negative annualized growth estimate) or the financial analysts are expecting a loss (negative estimated PE).
LT P/E
-20.20
-20.20
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
-13.70%
-13.70%
The annualized growth estimate is for the current year to 2028.
Avg. Nb analysts
19
19
Over the last seven weeks, an average of 19 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
127
127
For 1% of index variation, the stock varies on average by 1.27%.
Correlation
0.20
0.20
Stock movements are totally independent of index variations.
Value at Risk
20.38
20.38
The value at risk is estimated at USD 20.38. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
15.07.2025
15.07.2025